TY - JOUR AU - Wegiel, Barbara AU - Larsen, Rasmus AU - Gallo, David AU - Chin, Beek Yoke AU - Harris, Clair AU - Mannam, Praveen AU - Kaczmarek, Elzbieta AU - Lee, Patty J. AU - Zuckerbraun, Brian S. AU - Flavell, Richard AU - Soares, Miguel P. AU - Otterbein, Leo E. T1 - Macrophages sense and kill bacteria through carbon monoxide–dependent inflammasome activation PY - 2014/11/03/ AB - Microbial clearance by eukaryotes relies on complex and coordinated processes that remain poorly understood. The gasotransmitter carbon monoxide (CO) is generated by the stress-responsive enzyme heme oxygenase-1 (HO-1, encoded by Hmox1), which is highly induced in macrophages in response to bacterial infection. HO-1 deficiency results in inadequate pathogen clearance, exaggerated tissue damage, and increased mortality. Here, we determined that macrophage-generated CO promotes ATP production and release by bacteria, which then activates the Nacht, LRR, and PYD domains-containing protein 3 (NALP3) inflammasome, intensifying bacterial killing. Bacterial killing defects in HO-1–deficient murine macrophages were restored by administration of CO. Moreover, increased CO levels enhanced the bacterial clearance capacity of human macrophages and WT murine macrophages. CO-dependent bacterial clearance required the NALP3 inflammasome, as CO did not increase bacterial killing in macrophages isolated from NALP3-deficient or caspase-1–deficient mice. IL-1β cleavage and secretion were impaired in HO-1–deficient macrophages, and CO-dependent processing of IL-1β required the presence of bacteria-derived ATP. We found that bacteria remained viable to generate and release ATP in response to CO. The ATP then bound to macrophage nucleotide P2 receptors, resulting in activation of the NALP3/IL-1β inflammasome to amplify bacterial phagocytosis by macrophages. Taken together, our results indicate that macrophage-derived CO permits efficient and coordinated regulation of the host innate response to invading microbes. JF - The Journal of Clinical Investigation JA - J Clin Invest SN - 0021-9738 DO - 10.1172/JCI72853 VL - 124 IS - 11 UR - https://doi.org/10.1172/JCI72853 SP - 4926 EP - 4940 PB - The American Society for Clinical Investigation ER -